Abstract
Copper (Cu2+) is a physiologically important cation and is released from nerve terminals. Cu2+ modulates GABAA receptor currents in an α subunit subtype-dependent manner; α1β3γ2L receptors are more sensitive to Cu2+ than α6β3γ2L receptors. We compared the effect of Cu2+ on αβ3γ2L receptors containing each of the six α subtypes and generated α1/α6 chimeras and mutants to determine the functional domain(s) and specific residues responsible for α subtype-dependent differences in Cu2+ sensitivity. Whole-cell GABAA receptor currents were obtained from L929 fibroblasts coexpressing wild-type, chimeric and mutant α subunits with β3 and γ2L subunits. Maximal Cu2+ inhibition of α1β3γ2L and α2β3γ2L receptor currents was larger (52.2 ± 3.0 and 59.0 ± 2.5%, respectively) than maximal inhibition of α3β3γ2L, α4β3γ2L, α5β3γ2L, and α6β3γ2L receptor currents (22.6 ± 3.1, 19.2 ± 3.4, 20.2 ± 4.8, and 21.2 ± 3.6%, respectively). Receptors containing chimeric constructs with α1 subtype N-terminal sequence between residues 127 and 232 were inhibited by Cu2+ to an extent similar to those with α1 subtypes, suggesting that this N-terminal region (127-232) contains a major determinant for high Cu2+ sensitivity. α1 subtype residues V134, R135, and H141 in a VRAECPMH motif (VQAECPMH in the α2 subtype) conferred higher Cu2+ sensitivity, and the H141 residue was the major determinant in the motif. The β3 subtype M2 domain residue H267, which is a major determinant of Zn2+ inhibition, and α6 subtype M2-M3 loop residue H273, which is responsible for the increased Zn2+ sensitivity of the α6 subtype, also seemed to contribute to Cu2+ inhibition. These data suggest that the N-terminal VR(Q)AECPMH motif in α1 and α2 subtypes is the major determinant of increased subtype-dependent inhibition by Cu2+, that residue H141 is the major determinant in that motif, and that Cu2+ may also interact with GABAA receptors at sites similar to or overlapping Zn2+ sites.
- Received April 21, 2003.
- Accepted August 4, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|